|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||295.419 g/mol g·mol−1|
|3D model (JSmol)|
Glemanserin (INN) (developmental code name MDL-11,939) is a drug which acts as a potent and selective 5-HT2A receptor antagonist. The first truly selective 5-HT2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated analogue. Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinically for the treatment of generalized anxiety disorder. However, it was ultimately found to be ineffective and was not marketed.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|